What makes SGLT2i an ideal HF therapy?

Document ID: PC-MY-102951

24/07/2023

Author: Boehringer Ingelheim

What makes SGLT2i an ideal HF therapy? from Let's Talk! - Dr. James Januzzi

Click on the timestamp to jump to the topic you are interested in.

  • 00:17 What makes SGLT2i an ideal HF therapy? 00:56 EMPEROR-Reduced demonstrates no clinically meaningful difference in adverse events 01:47 EMPEROR-Reduced: Safety in patients with and without diabetes 02:33 Is empagliflozin just as safe in the EMPEROR-Preserved study? 02:54 What can we say about the adverse event trends in EMPEROR-Preserved?

123,000
Views

100k 340

Related content

 
PC-MY-102951
Production date: July 2023